News: Fibrocell Equity Offering $FCSC

Fibrocell Science, Inc., an autologous cell and gene therapy company, has announced the pricing of its Equity Offering.

The firm has announced the pricing of an underwritten public offering of 2.6 million shares of its common stock at a price of $5.80 per share. Gross proceeds will be approximately $13.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Fibrocell intends to use the net proceeds of the offering for the continued clinical and preclinical development of its product candidates and for other general corporate purposes.

View the full release here.